SCHEMBL20157320

SCHEMBL20157320

COc1ccc(-c2cn(C)c(=O)cc2CNC(=O)OC(C)(C)C)c(C(=O)c2ccc(F)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.41
GAA P10253 2/20 0.40
RXFP1 Q9HBX9 1/20 0.38
MAPT P10636 5/20 0.38
TP53 P04637 3/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
BRD4 O60885 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157374 0.93 EPHX2 (0.41) EPHX2GAARXFP1MAPTTP53
SCHEMBL20157599 0.92 MAPT (0.38) MAPTTP53KMT2ASMN1; SMN2HSD17B10
SCHEMBL20157896 0.84 BRD4 (0.35) MAPTBRD4THRBKCNA5
SCHEMBL20157758 0.83 RAF1 (0.40) BRD4
SCHEMBL21362121 0.82 BRD4 (0.34) GAABRD4TUBB4ATUBBTUBA3C
SCHEMBL20157838 0.82 RAF1 (0.36) RXFP1SMN1; SMN2BRD4ALDH1A1
SCHEMBL20158054 0.80 BRD4 (0.41) EPHX2BRD4
SCHEMBL21362513 0.79 GRM2 (0.35) SMN1; SMN2BRD4THRBKCNA5
SCHEMBL20157755 0.79 BRD4 (0.35) MAPTBRD4THRBKCNA5
SCHEMBL20157810 0.79 BRD4 (0.46) GAAKMT2ASMN1; SMN2KDM4EBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 EPHX2 4659/4885GAA 4852/4885RXFP1 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.